Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 18/20 | 0.44 |
| ▸ | ERBB3 | P21860 | 4/20 | 0.44 |
| ▸ | ERBB4 | Q15303 | 4/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2747871 | 0.90 | FGFR1 (0.41) | EGFRERBB2ERBB3ERBB4FGFR1 | |
| SCHEMBL3403862 | 0.85 | FGFR1 (0.40) | EGFRERBB2ERBB3ERBB4FGFR1 | |
| SCHEMBL27684259 | 0.83 | FGFR1 (0.42) | EGFRERBB2ERBB3ERBB4FGFR1 | |
| SCHEMBL2748776 | 0.83 | FGFR1 (0.40) | EGFRERBB2ERBB3ERBB4FGFR1 | |
| SCHEMBL2749135 | 0.83 | FGFR1 (0.40) | EGFRERBB2ERBB3ERBB4FGFR1 | |
| SCHEMBL2748523 | 0.83 | FGFR1 (0.42) | EGFRERBB2ERBB3ERBB4FGFR1 | |
| SCHEMBL3506358 | 0.81 | FGFR1 (0.39) | EGFRERBB2ERBB3ERBB4FGFR1 | |
| SCHEMBL3509903 | 0.80 | FGFR1 (0.38) | EGFRERBB2ERBB3ERBB4FGFR1 | |
| SCHEMBL2749112 | 0.80 | FGFR1 (0.53) | FGFR1FGFR4 | |
| SCHEMBL27664616 | 0.80 | TLR8 (0.44) | FGFR1FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3792264-B1 | PYRROPYRIMIDINE COMPOUNDS AS MNKS INHIBITORS | LIFEARC (GB) | 2024-01-03 | — | — | EP | disclosed |
| CN-108368114-B | Pyrrolopyrimidine compounds as MNK inhibitors | 生命弧度公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-3792264-A1 | PYRROPYRIMIDINE COMPOUNDS AS MNKS INHIBITORS | LifeArc (GB) | 2021-03-17 | — | — | EP | disclosed |
| EP-3792264-A1 | PYRROPYRIMIDINE COMPOUNDS AS MNKS INHIBITORS | LifeArc (GB) | 2021-03-17 | — | — | EP | disclosed |
| EP-3377494-B1 | PYRROPYRIMIDINE COMPOUNDS AS MNKS INHIBITORS | LIFEARC (GB) | 2021-03-03 | — | — | EP | disclosed |
| EP-3377494-B1 | PYRROPYRIMIDINE COMPOUNDS AS MNKS INHIBITORS | LIFEARC (GB) | 2021-03-03 | — | — | EP | disclosed |
| US-10604524-B2 | Pyrropyrimidine compounds as MNKs inhibitors | LIFE ARC (GB) | 2020-03-31 | — | — | US | disclosed |
| US-20180346469-A1 | Pyrropyrimidine Compounds As MNKS Inhibitors | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2018-12-06 | — | — | US | disclosed |
| EP-3377494-A1 | PYRROPYRIMIDINE COMPOUNDS AS MNKS INHIBITORS | LifeArc (GB) | 2018-09-26 | — | — | EP | disclosed |
| EP-1752457-B1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-03-19 | — | — | EP | disclosed |
| US-8178543-B2 | growth factor receptor tyrosine kinase inhibitor; anticarcinogenic agents; N-{2-[4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl}-3-hydroxy-3-methylbutanamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| CN-1993362-B | Fused Heterocyclic Compounds | TAKEDA PHARMACEUTICAL | 2010-12-15 | — | — | CN | disclosed |
| US-20090203717-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-13 | — | — | US | disclosed |
| US-7507740-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-24 | — | — | US | disclosed |
| US-20090029973-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20090018335-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20070244132-A1 | Fused Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-18 | — | — | US | disclosed |
| CN-1993362-A | Fused Heterocyclic Compounds | TAKEDA PHARMACEUTICAL (JP) | 2007-07-04 | — | — | CN | disclosed |
| EP-1752457-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203717-A1 | FUSED HETEROCYCLIC COMPOUND | NOX3, ERBB3, CBR3 | EGFR 68/4885ERBB2 21/4885ERBB3 2/4885 |
| US-20070244132-A1 | Fused Heterocyclic Compound | NOX3, ERBB3, CBR3 | EGFR 68/4885ERBB2 21/4885ERBB3 2/4885 |
| US-20180346469-A1 | Pyrropyrimidine Compounds As MNKS Inhibitors | NR0B1, NR4A1, NR2E1 | EGFR 789/4885ERBB2 663/4885ERBB3 929/4885 |
| US-10604524-B2 | Pyrropyrimidine compounds as MNKs inhibitors | NR0B1, NR2E1, HRH4 | EGFR 806/4885ERBB2 668/4885ERBB3 987/4885 |
| US-20090029973-A1 | FUSED HETEROCYCLIC COMPOUND | NOX3, ERBB3, CBR3 | EGFR 68/4885ERBB2 21/4885ERBB3 2/4885 |
| US-20090018335-A1 | FUSED HETEROCYCLIC COMPOUND | NOX3, ERBB3, CBR3 | EGFR 68/4885ERBB2 21/4885ERBB3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.